DERMABOND ADVANCED® Topical Skin Adhesive

DERMABOND ADVANCED Adhesive provides strength to maintain barrier and wound closure integrity.1,2 DERMABOND ADVANCED is demonstrated in vitro to kill 99.9% of bacteria (MRSA, MRSE, and E. coli) on direct contact.3

DERMABOND ADVANCED 
Topical Skin Adhesive

Features & Benefits

Additional Strength 
for Secure Closure

Additional Strength 
for Secure Closure

When used in addition to sutures, DERMABOND ADVANCED Adhesive was shown ex vivo to add 75% more strength to wound closure than 
sutures alone.4

Microbial Barrier Protection

Microbial Barrier Protection5
 

DERMABOND ADVANCED Adhesive provides a microbial barrier with 99% protection in vitro for at least 72 hours against organisms commonly responsible for surgical site infections (SSIs). 5**

Extensive Clinical Evidence

Extensive Clinical Evidence

DERMABOND Advanced Adhesive 
is supported by substantially more Randomized Controlled Trials (RCTs) than the top six competitors combined.6-8,*†‡

A Precisely Balanced Formulation Unlike any other TSA on the Market

A Precisely Balanced Formulation Unlike any other TSA on the Market

Our proprietary formulation has 3 main components: a monomer, initiator, 
and additives. Different ratios of these components can impact the performance of the adhesive. Our formulation is a precisely balanced combination of these components.

Product Specifications

Product Code

Product Code

Description

 
DNX12 DNX12 DERMABOND ADVANCED TOPICAL SKIN ADHESIVE - UNIQUE FORMULATION WITH AN EASY-TO-USE APPLICATOR FOR PRECISE CONTROL FOR WIDE AND FINE LINE APPLICATIONS; 0.7ML ADHESIVE VOLUME 

Product Code

Product Code

Description

 
DNX6 DNX6 DERMABOND ADVANCED TOPICAL SKIN ADHESIVE - UNIQUE FORMULATION WITH AN EASY-TO-USE APPLICATOR FOR PRECISE CONTROL FOR WIDE AND FINE LINE APPLICATIONS; 0.7ML ADHESIVE VOLUME 

Resources

DERMABOND ADVANCED Topical Skin Adhesive Application Video

Supporting Documentation

Clinical Evidence

DERMABOND ADVANCED Adhesive Clinical Evidence Summary

Product Support

DERMABOND ADVANCED® Topical Skin Adhesive Brochure

DERMABOND ADVANCED® Topical Skin Adhesive Patient Care Instruction Pad

DERMABOND ADVANCED® Topical Skin Adhesive Proof vs. Perception

Understanding the Health Care Landscape: The Affordable Care Act

DERMABOND ADVANCED® Topical Skin Adhesive vs. Advanced Medical Solutions Cardinal Health Liquidband OCTYL Topical Skin Adhesive

DERMABOND ADVANCED Liquiband Competitive Rebuttal

DERMABOND ADVANCED® Topical Skin Adhesive Optimal Device Performance Guide

References

**Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.

*DERMABOND ADVANCED Adhesive tests equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound-bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.

†Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.

‡Top 6 US competitors include LiquiBand®, Skin Aix™, SwiftSet™, SurgiSeal®, Derma+Flex® QS™, and Histoacryl®.

 1. Quinn J, Wells G, Sutcliffe T, et al. A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations. JAMA. 1997;277(19):1527-1530.

2. Singer AJ, Perry LC, Allen RL. In vivo study of wound-bursting strength and compliance of topical skin adhesives. Acad Emerg Med. 2008;15(12):1290-1294.

3. Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of DERMABOND® Topical Skin Adhesive. Surg Infect (Larchmt). 2002;3(3):251-257.

4. Report: Protocol to determine the strength benefits when adding DERMABOND™ ADVANCED Topical Skin Adhesive to a wound or incision using suture as the primary closure.

5. Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of DERMABOND® Topical Skin Adhesive.Surg Infect (Larchmt).2002;3(3):251-257.

6. Ethicon US Market Share Report, October 2016.

7. Dermabond RCT List, Jan 2017.

8. Competitive TSA RCT Summary.

9. Singer AJ, Perry L. A comparative study of the surgically relevant mechanical characteristics of the topical skin adhesives. Acad Emerg Med. 2012;19(11):1281-86.

10. Keplinger, S. Comparison of setting times of topical skin adhesive products. Report 11TR053. August 16, 2011. Ethicon, Inc.

11. U.S. Food & Drug Administration. DERMABOND® NX Topical Skin Adhesive Approval Letter. May 4, 2010. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100423.pdf. Accessed October 11, 2018.


For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.